Rashmi Jindal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rashmi Jindal has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Payal Chauhan
Department of Dermatology, All India Institute of Medical Sciences, Jammu, Jammu and Kashmir, India
12 shared publications Payal Chauhan
Department of Dermatology, Venereology & Leprosy, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun, Uttarakhand, India
10 shared publicationsNadia Shirazi
Department of Pathology, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun, Uttarakhand, India
8 shared publicationsSheenam Sethi
Department of Dermatology, Himalayan Institute of Medical sciences, Dehradun, Uttarakhand, India
8 shared publicationsSamarjit Roy
Department of Dermatology, Venereology and Leprosy, Himalayan Institute of Medical Sciences, Dehradun, India
7 shared publicationsDilip Meena
Department of Dermatology, Venereology and Leprology, Teerthanker Mahaveer Medical College and Research Centre, Moradabad, Uttar Pradesh, India
4 shared publications
Latest Publications
- Open Access
- 31 December 2025
- Published by Wolters Kluwer Health in Indian Journal of Dermatology
- Vol. 71 (1) , 1-11
A Comparative Study on the Measurement Properties (Criterion Validity, Informativity, and Floor and Ceiling Effects) of Dermatology Life Quality Index (DLQI) and Skindex-29
Background: The measurement of health-related quality of life (HRQoL) is essential in dermatology, with the DLQI and Skindex-29 being popular tools for assessment. However, the literature comparing the measuring features of these two questionnaires is lacking. Aims: This study aims to provide a comparison of the measurement properties of DLQI and Skindex-29 in patients with common dermatology conditions such as psoriasis vulgaris (PV), vitiligo vulgaris (VV), leprosy, and acne vulgaris (AV). Methods: In this cross-sectional study, the HRQoL of 301 patients with the four dermatological conditions was measured using the DLQI and Skindex-29 questionnaires at a tertiary care centre located in Dehradun, Uttarakhand, India. Statistical analysis included determining ceiling and floor effects, informativity, and criterion validity. Results: The mean DLQI total scores were: PV (11.03 ± 0.89), VV (4.73 ± 0.78), leprosy (8.97 ± 1.09), and AV (7.79 ± 0.63), and the mean Skindex-29 scores were: PV (37.98 ± 2.82), VV (27.92 ± 2.93), leprosy (45.12 ± 3.63), and AV (27.6 ± 1.08), with a 95% confidence interval. Of the patients with a DLQI score of 0 (n = 66), 64 (96%) had a total score greater than 0 on the Skindex-29. The most troubled areas of HRQoL among patients with a DLQI score of 0 according to the Skindex-29 were item 17 (showing affection; 12.1%), item 9 (worry about scars; 9.1%), item 12, item 13, and item 14 (being ashamed, worrying about worsening, and tending to do things oneself; 7.6%). The ceiling effect was observed in 4.7% of patients for DLQI and 0% for Skindex-29. The floor effect was high for the DLQI total score (22%), whereas Skindex-29 observed only 0.7%. The absolute informativity value of Skindex-29 was 1.66, and that of the DLQI was 1.92. The typical relative informativity value for both was 0.83. Conclusion: Skindex-29 showed better sensitivity to clinical severity, less floor effect, higher absolute informativity, and better coverage of the ‘emotion’ domain. Skindex-29 was found to be more effective in detecting minor HRQoL impairment than DLQI.
- 31 December 2025
- Published by Wolters Kluwer Health in Indian Journal of Dermatology
- Vol. 71 (1) , 1-11
Open AccessA Comparative Study on the Measurement Properties (Criterion Validity, Informativity, and Floor and Ceiling Effects) of Dermatology Life Quality Index (DLQI) and Skindex-29
Background: The measurement of health-related quality of life (HRQoL) is essential in dermatology, with the DLQI and Skindex-29 being popular tools for assessment. However, the literature comparing the measuring features of these two questionnaires is lacking. Aims: This study aims to provide a comparison of the measurement properties of DLQI and Skindex-29 in patients with common dermatology conditions such as psoriasis vulgaris (PV), vitiligo vulgaris (VV), leprosy, and acne vulgaris (AV). Methods: In this cross-sectional study, the HRQoL of 301 patients with the four dermatological conditions was measured using the DLQI and Skindex-29 questionnaires at a tertiary care centre located in Dehradun, Uttarakhand, India. Statistical analysis included determining ceiling and floor effects, informativity, and criterion validity. Results: The mean DLQI total scores were: PV (11.03 ± 0.89), VV (4.73 ± 0.78), leprosy (8.97 ± 1.09), and AV (7.79 ± 0.63), and the mean Skindex-29 scores were: PV (37.98 ± 2.82), VV (27.92 ± 2.93), leprosy (45.12 ± 3.63), and AV (27.6 ± 1.08), with a 95% confidence interval. Of the patients with a DLQI score of 0 (n = 66), 64 (96%) had a total score greater than 0 on the Skindex-29. The most troubled areas of HRQoL among patients with a DLQI score of 0 according to the Skindex-29 were item 17 (showing affection; 12.1%), item 9 (worry about scars; 9.1%), item 12, item 13, and item 14 (being ashamed, worrying about worsening, and tending to do things oneself; 7.6%). The ceiling effect was observed in 4.7% of patients for DLQI and 0% for Skindex-29. The floor effect was high for the DLQI total score (22%), whereas Skindex-29 observed only 0.7%. The absolute informativity value of Skindex-29 was 1.66, and that of the DLQI was 1.92. The typical relative informativity value for both was 0.83. Conclusion: Skindex-29 showed better sensitivity to clinical severity, less floor effect, higher absolute informativity, and better coverage of the ‘emotion’ domain. Skindex-29 was found to be more effective in detecting minor HRQoL impairment than DLQI.
- Open Access
- 9 October 2025
- Published by Scientific Scholar in Indian Journal of Dermatology, Venereology and Leprology
- Vol. 92 (1) , 37-42
Resistance to anti-leprosy drugs in multi-bacillary leprosy patients: The need for transformative action
Background: Leprosy, caused by Mycobacterium leprae , remains a significant public health challenge, particularly in endemic regions. While multidrug therapy (MDT) has been effective, the emergence of antimicrobial resistance (AMR) to key drugs such as rifampicin, dapsone, and ofloxacin threatens leprosy control programs. Resistance mechanisms include mutations in genes such as rpoB (rifampicin), folP1 (dapsone), and gyrA (ofloxacin). Drug resistance contributes to treatment failures, prolonged transmission, and the emergence of severe complications, necessitating enhanced surveillance and diagnostic capabilities. Aims: This study aimed to determine the rates of primary and secondary AMR in M. leprae among multi-bacillary leprosy patients attending a tertiary care institute in Uttarakhand. It also sought to identify patterns of genetic mutations associated with resistance. Methods: This prospective, cross-sectional study was conducted from July 2022 to June 2024. Patients with a bacteriological index (BI) ≥2, fulfilling specific clinical criteria [treatment-naive, chronic or recurrent erythema nodosum leprosum (ENL), relapse or persistent positive morphological index (MI)] were recruited. Slit skin smears (SSS) were processed using polymerase chain reaction (PCR) -based gene amplification to detect mutations in rpoB , folP1 and gyrA . Amplified DNA samples were sequenced and analysed for resistance-associated mutations. Demographic and clinical data, including type of leprosy, BI, MI, and treatment history, were also collected. Results: Out of 47 samples tested, 43 were successfully amplified. Resistance was detected in eight cases (17%). Primary resistance was noted in 4/20 treatment-naive patients (20%). Rifampicin resistance, attributed to the F439L mutation, was the most common (n = 4). Dapsone resistance due to P55L and P55S mutations was identified in two cases, while ofloxacin resistance associated with A91V and G89C mutations was seen in two cases. Limitations: The study’s findings are limited by its sample size and the focus on a single tertiary care centre, potentially restricting the generalisability of results. Additionally, not all samples were successfully amplified for analysis. Conclusion: This study underscores the critical need for routine AMR testing in high-risk leprosy cases. Regional variations in resistance patterns necessitate localised surveillance to guide effective treatment strategies. Enhanced diagnostic capabilities, patient education, and policy-level interventions are essential to combat the rising threat of AMR in leprosy.
- 9 October 2025
- Published by Scientific Scholar in Indian Journal of Dermatology, Venereology and Leprology
- Vol. 92 (1) , 37-42
Open AccessResistance to anti-leprosy drugs in multi-bacillary leprosy patients: The need for transformative action
Background: Leprosy, caused by Mycobacterium leprae , remains a significant public health challenge, particularly in endemic regions. While multidrug therapy (MDT) has been effective, the emergence of antimicrobial resistance (AMR) to key drugs such as rifampicin, dapsone, and ofloxacin threatens leprosy control programs. Resistance mechanisms include mutations in genes such as rpoB (rifampicin), folP1 (dapsone), and gyrA (ofloxacin). Drug resistance contributes to treatment failures, prolonged transmission, and the emergence of severe complications, necessitating enhanced surveillance and diagnostic capabilities. Aims: This study aimed to determine the rates of primary and secondary AMR in M. leprae among multi-bacillary leprosy patients attending a tertiary care institute in Uttarakhand. It also sought to identify patterns of genetic mutations associated with resistance. Methods: This prospective, cross-sectional study was conducted from July 2022 to June 2024. Patients with a bacteriological index (BI) ≥2, fulfilling specific clinical criteria [treatment-naive, chronic or recurrent erythema nodosum leprosum (ENL), relapse or persistent positive morphological index (MI)] were recruited. Slit skin smears (SSS) were processed using polymerase chain reaction (PCR) -based gene amplification to detect mutations in rpoB , folP1 and gyrA . Amplified DNA samples were sequenced and analysed for resistance-associated mutations. Demographic and clinical data, including type of leprosy, BI, MI, and treatment history, were also collected. Results: Out of 47 samples tested, 43 were successfully amplified. Resistance was detected in eight cases (17%). Primary resistance was noted in 4/20 treatment-naive patients (20%). Rifampicin resistance, attributed to the F439L mutation, was the most common (n = 4). Dapsone resistance due to P55L and P55S mutations was identified in two cases, while ofloxacin resistance associated with A91V and G89C mutations was seen in two cases. Limitations: The study’s findings are limited by its sample size and the focus on a single tertiary care centre, potentially restricting the generalisability of results. Additionally, not all samples were successfully amplified for analysis. Conclusion: This study underscores the critical need for routine AMR testing in high-risk leprosy cases. Regional variations in resistance patterns necessitate localised surveillance to guide effective treatment strategies. Enhanced diagnostic capabilities, patient education, and policy-level interventions are essential to combat the rising threat of AMR in leprosy.
- Open Access
- 5 July 2025
- Published by Wolters Kluwer Health in Clinical Dermatology Review
- Vol. 9 (3) , 310-311
Hereditary Papulotranslucent Acrokeratoderma in a 14-year-old Girl
- 5 July 2025
- Published by Wolters Kluwer Health in Clinical Dermatology Review
- Vol. 9 (3) , 310-311
Open AccessHereditary Papulotranslucent Acrokeratoderma in a 14-year-old Girl
- Open Access
- 13 February 2025
- Published by Scientific Scholar in Indian Journal of Skin Allergy
- Vol. 4 (1) , 43-51
Genital contact dermatitis
The genital region is uniquely susceptible to both irritant and allergic contact dermatitis (ACD) due to its delicate anatomy, moist environment, and frequent exposure to potential irritants and allergens. Factors such as friction, maceration, and overuse of hygiene products significantly compromise the skin barrier, increasing the risk of dermatitis. The region’s sensitivity is further exacerbated by physiological changes, such as reduced estrogen levels in postmenopausal women, which heighten susceptibility to external agents. A detailed clinical history plays a critical role in diagnosing genital contact dermatitis (CD). Key elements include symptom onset, triggers, hygiene habits, and exposure to products used personally or by sexual partners. This thorough exploration often identifies potential irritants and allergens overlooked in a routine examination. Irritant CD (ICD) in the genital area typically presents as burning, stinging, and erythema soon after exposure to irritants. Chronic ICD may lead to scaling and lichenification. In contrast, ACD arises from delayed hypersensitivity to allergens, presenting as pruritus, erythema, and, in severe cases, vesiculobullous eruptions. Common agents implicated in ICD include soaps, urine, sweat, and certain hygiene sprays, while ACD is often triggered by allergens such as fragrances, topical medications, preservatives, and rubber components. Patch testing is a cornerstone of diagnosing genital ACD. It identifies specific allergens responsible for the dermatitis and helps in differentiating between relevant and incidental reactions. Expanding patch test series to include additional potential allergens, such as personal care products or items used by partners, enhances diagnostic accuracy. The repeat open application test is another valuable tool, particularly when patch testing yields inconclusive results. Management of genital CD primarily involves strict avoidance of identified irritants and allergens. Patients should cease using unnecessary topical medications and adopt hypoallergenic alternatives. Education on proper genital care, including the use of fragrance-free and dye-free products, is essential. Topical corticosteroids, calcineurin inhibitors, or phosphodiesterase-4 inhibitors may be prescribed for short-term relief.
- 13 February 2025
- Published by Scientific Scholar in Indian Journal of Skin Allergy
- Vol. 4 (1) , 43-51
Open AccessGenital contact dermatitis
The genital region is uniquely susceptible to both irritant and allergic contact dermatitis (ACD) due to its delicate anatomy, moist environment, and frequent exposure to potential irritants and allergens. Factors such as friction, maceration, and overuse of hygiene products significantly compromise the skin barrier, increasing the risk of dermatitis. The region’s sensitivity is further exacerbated by physiological changes, such as reduced estrogen levels in postmenopausal women, which heighten susceptibility to external agents. A detailed clinical history plays a critical role in diagnosing genital contact dermatitis (CD). Key elements include symptom onset, triggers, hygiene habits, and exposure to products used personally or by sexual partners. This thorough exploration often identifies potential irritants and allergens overlooked in a routine examination. Irritant CD (ICD) in the genital area typically presents as burning, stinging, and erythema soon after exposure to irritants. Chronic ICD may lead to scaling and lichenification. In contrast, ACD arises from delayed hypersensitivity to allergens, presenting as pruritus, erythema, and, in severe cases, vesiculobullous eruptions. Common agents implicated in ICD include soaps, urine, sweat, and certain hygiene sprays, while ACD is often triggered by allergens such as fragrances, topical medications, preservatives, and rubber components. Patch testing is a cornerstone of diagnosing genital ACD. It identifies specific allergens responsible for the dermatitis and helps in differentiating between relevant and incidental reactions. Expanding patch test series to include additional potential allergens, such as personal care products or items used by partners, enhances diagnostic accuracy. The repeat open application test is another valuable tool, particularly when patch testing yields inconclusive results. Management of genital CD primarily involves strict avoidance of identified irritants and allergens. Patients should cease using unnecessary topical medications and adopt hypoallergenic alternatives. Education on proper genital care, including the use of fragrance-free and dye-free products, is essential. Topical corticosteroids, calcineurin inhibitors, or phosphodiesterase-4 inhibitors may be prescribed for short-term relief.
- Open Access
- 20 January 2025
- Published by Wolters Kluwer Health in Indian Dermatology Online Journal
- Vol. 16 (2) , 352-353
Phthiriasis Palpebrarum: Dermoscopy to Rescue
- 20 January 2025
- Published by Wolters Kluwer Health in Indian Dermatology Online Journal
- Vol. 16 (2) , 352-353
Open AccessPhthiriasis Palpebrarum: Dermoscopy to Rescue
- 2 August 2024
- Vol. 22 (2) , 150-152
Sneddon's Syndrome with Underlying Protein S Deficiency and Decreased Protein C Activity.
- 2 August 2024
- Vol. 22 (2) , 150-152
Sneddon's Syndrome with Underlying Protein S Deficiency and Decreased Protein C Activity.
- Open Access
- 6 June 2023
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 13 (2) , 60-65
Management of hereditary angioedema in resource-constrained settings: A consensus statement from Indian subcontinent
Hereditary angioedema (HAE) is an uncommon disorder characterized clinically by recurrent episodes of nonitchy subcutaneous and/or submucosal swellings. The estimated prevalence of HAE is ~ 1: 10,000 to 1: 50,000. There are no prevalence data from India, however, estimates suggest that there are 27,000 to 135,000 patients with HAE in India at present. The majority of these, however, remain undiagnosed. Replacement of plasma-derived or recombinant C1-esterase inhibitor (C1-INH) protein, administered intravenously, is the treatment of choice during the management of acute episodes of angioedema (i.e., “on-demand treatment”) and is also useful for short-term prophylaxis (STP) and long-term prophylaxis (LTP). This has been found to be effective and safe even in young children and during pregnancy. Until recently, none of the first-line treatment options were available for “on-demand treatment,” STP or LTP in India. As a result, physicians had to use fresh frozen plasma for both “on-demand treatment” and STP. For LTP, attenuated androgens (danazol or stanozolol) and/or tranexamic acid were commonly used. These drugs have been reported to be useful for LTP but are associated with a significant risk of adverse effects. Intravenous pd-C1-INH, the first-line treatment option, is now available in India. However, because there is no universal health insurance, access to pd-C1-INH is a significant challenge. HAE Society of India has developed these consensus guidelines for India and other resource-constrained settings where plasma-derived C1-INH therapy is the only available first-line treatment option for the management of HAE and diagnostic facilities are limited. These guidelines have been developed because it may not be possible for all patients to access the recommended therapy and at the recommended doses as suggested by the international guidelines. Moreover, it may not be feasible to follow the evaluation algorithm suggested by the international guidelines.
- 6 June 2023
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 13 (2) , 60-65
Open AccessManagement of hereditary angioedema in resource-constrained settings: A consensus statement from Indian subcontinent
Hereditary angioedema (HAE) is an uncommon disorder characterized clinically by recurrent episodes of nonitchy subcutaneous and/or submucosal swellings. The estimated prevalence of HAE is ~ 1: 10,000 to 1: 50,000. There are no prevalence data from India, however, estimates suggest that there are 27,000 to 135,000 patients with HAE in India at present. The majority of these, however, remain undiagnosed. Replacement of plasma-derived or recombinant C1-esterase inhibitor (C1-INH) protein, administered intravenously, is the treatment of choice during the management of acute episodes of angioedema (i.e., “on-demand treatment”) and is also useful for short-term prophylaxis (STP) and long-term prophylaxis (LTP). This has been found to be effective and safe even in young children and during pregnancy. Until recently, none of the first-line treatment options were available for “on-demand treatment,” STP or LTP in India. As a result, physicians had to use fresh frozen plasma for both “on-demand treatment” and STP. For LTP, attenuated androgens (danazol or stanozolol) and/or tranexamic acid were commonly used. These drugs have been reported to be useful for LTP but are associated with a significant risk of adverse effects. Intravenous pd-C1-INH, the first-line treatment option, is now available in India. However, because there is no universal health insurance, access to pd-C1-INH is a significant challenge. HAE Society of India has developed these consensus guidelines for India and other resource-constrained settings where plasma-derived C1-INH therapy is the only available first-line treatment option for the management of HAE and diagnostic facilities are limited. These guidelines have been developed because it may not be possible for all patients to access the recommended therapy and at the recommended doses as suggested by the international guidelines. Moreover, it may not be feasible to follow the evaluation algorithm suggested by the international guidelines.
- Open Access
- 16 March 2023
- Published by International Scientific Invention Journals in International Journal of Innovative Research in Medical Science
- Vol. 8 (03) , 107-112
Skin Biopsies in Gastrointestinal Diseases: A Single Centre Experience from North India
Skin manifestations have always been alarming to the patient and often warrant complete clinical evaluation. A thorough understanding of relationship between gastrointestinal (GI) disorders and skin diseases can alert the clinician to an underlying occult GI disorder. The aim of the study was to review the cutaneous changes in patients with co-existent, often masked GI diseases and to observe the underlying pathophysiology of such lesions. This was a retrospective, record based observational study. The archived histopathology reports & medical records of patients over a period of 5 years were searched and all patients who underwent skin biopsy with co-existent GI diseases were included. Out of a total of 218 patients of GI diseases who had dermatological manifestations, only 44 were biopsied. Pruritis (n=175), koilonychia (n=52) and erythematous rash (n=35) were the most common clinical features. Psoriasis (n=4), vasculitis (n=4), Dermatitis Herpetiformis (n=3) and pyoderma gangrenosum (n=5) were often seen associated with benign GI diseases like Inflammatory Bowel Diseases, Chronic Liver Disease, Malabsorption syndrome etc. Sweets syndrome (n=2) and cutaneous metastatic nodules (n=3) were associated with underlying malignancy particularly of gall bladder and pancreas.
- 16 March 2023
- Published by International Scientific Invention Journals in International Journal of Innovative Research in Medical Science
- Vol. 8 (03) , 107-112
Open AccessSkin Biopsies in Gastrointestinal Diseases: A Single Centre Experience from North India
Skin manifestations have always been alarming to the patient and often warrant complete clinical evaluation. A thorough understanding of relationship between gastrointestinal (GI) disorders and skin diseases can alert the clinician to an underlying occult GI disorder. The aim of the study was to review the cutaneous changes in patients with co-existent, often masked GI diseases and to observe the underlying pathophysiology of such lesions. This was a retrospective, record based observational study. The archived histopathology reports & medical records of patients over a period of 5 years were searched and all patients who underwent skin biopsy with co-existent GI diseases were included. Out of a total of 218 patients of GI diseases who had dermatological manifestations, only 44 were biopsied. Pruritis (n=175), koilonychia (n=52) and erythematous rash (n=35) were the most common clinical features. Psoriasis (n=4), vasculitis (n=4), Dermatitis Herpetiformis (n=3) and pyoderma gangrenosum (n=5) were often seen associated with benign GI diseases like Inflammatory Bowel Diseases, Chronic Liver Disease, Malabsorption syndrome etc. Sweets syndrome (n=2) and cutaneous metastatic nodules (n=3) were associated with underlying malignancy particularly of gall bladder and pancreas.
- Open Access
- 7 February 2023
- Published by Scientific Scholar in Indian Journal of Postgraduate Dermatology
- Vol. 1 (1) , 35-38
Opportunities for Residents through the Indian Association of Dermatologists, Venereologists and Leprologists
Indian Association of Dermatologists, Venereologists and Leprologists is actively involved in providing its members diverse opportunities for academic growth. The residents during post graduation can avail post graduate thesis grants and scholarships. IADVL observerships and trainings are more suitable immediately after completing post graduation. Many awards including the PG thesis based award paper session is an excellent opportunity to present the research work conducted during residency. Apart from this the IADVL digital academy platform is an excellent learning resource.
- 7 February 2023
- Published by Scientific Scholar in Indian Journal of Postgraduate Dermatology
- Vol. 1 (1) , 35-38
Open AccessOpportunities for Residents through the Indian Association of Dermatologists, Venereologists and Leprologists
Indian Association of Dermatologists, Venereologists and Leprologists is actively involved in providing its members diverse opportunities for academic growth. The residents during post graduation can avail post graduate thesis grants and scholarships. IADVL observerships and trainings are more suitable immediately after completing post graduation. Many awards including the PG thesis based award paper session is an excellent opportunity to present the research work conducted during residency. Apart from this the IADVL digital academy platform is an excellent learning resource.
- Open Access
- 1 January 2023
- Published by Medknow in Indian Journal of Dermatology
- Vol. 68 (1) , 120
Dermoscopy in the Diagnosis of Palmoplantar Eczema and Palmoplantar Psoriasis
Introduction: Palmoplantar hyperkeratotic lesions pose a diagnostic difficulty when differentiating clinically between palmoplantar psoriasis (PPP) and palmoplantar eczema (PPE). Dermoscopy can provide valuable clues in reaching the final diagnosis. Objectives: To identify and compare dermoscopic findings seen in PPP and PPE. Methods: This was a cross-sectional, comparative study carried out prospectively between March 2019 and June 2020. All adult, consenting patients visiting the dermatology outpatient department who were clinically diagnosed and histopathologically confirmed as PPP and PPE were recruited into two groups. The dermoscopic examination was done, and images were taken from the representative area. The findings were analysed by two dermatologists who were unaware of the diagnosis. The sensitivity, specificity, positive predictive value and negative predictive value of these findings were assessed. Result: A total of 81 patients were recruited (39 patients of PPP and 42 patients of PPE). Significant findings seen in psoriatic plaques were the presence of regular vessels (84.6%, P < 0.001), with diffuse scales (87.2%) over a dull red/pink background (69.2%, P < 0.001). Dermoscopy of PPE displayed a significant presence of yellowish scales (76.2%, P < 0.001), with focal (61.9%) or absent vessels (35.7%), brown/orange-brown dots and/or globules (66.7%), yellow/yellow-orange crusts (57.1%) over a yellow/yellow-brown background (88.1%). Conclusion: Distribution of vessels, distribution of scales and the colour of scales, presence of brown/orange-brown dots and/or globules, yellow/yellow-orange crust and background colour (dull red vs. yellow/yellow-brown) of the plaques can be useful clues in the diagnosis of PPP and PPE.
- 1 January 2023
- Published by Medknow in Indian Journal of Dermatology
- Vol. 68 (1) , 120
Open AccessDermoscopy in the Diagnosis of Palmoplantar Eczema and Palmoplantar Psoriasis
Introduction: Palmoplantar hyperkeratotic lesions pose a diagnostic difficulty when differentiating clinically between palmoplantar psoriasis (PPP) and palmoplantar eczema (PPE). Dermoscopy can provide valuable clues in reaching the final diagnosis. Objectives: To identify and compare dermoscopic findings seen in PPP and PPE. Methods: This was a cross-sectional, comparative study carried out prospectively between March 2019 and June 2020. All adult, consenting patients visiting the dermatology outpatient department who were clinically diagnosed and histopathologically confirmed as PPP and PPE were recruited into two groups. The dermoscopic examination was done, and images were taken from the representative area. The findings were analysed by two dermatologists who were unaware of the diagnosis. The sensitivity, specificity, positive predictive value and negative predictive value of these findings were assessed. Result: A total of 81 patients were recruited (39 patients of PPP and 42 patients of PPE). Significant findings seen in psoriatic plaques were the presence of regular vessels (84.6%, P < 0.001), with diffuse scales (87.2%) over a dull red/pink background (69.2%, P < 0.001). Dermoscopy of PPE displayed a significant presence of yellowish scales (76.2%, P < 0.001), with focal (61.9%) or absent vessels (35.7%), brown/orange-brown dots and/or globules (66.7%), yellow/yellow-orange crusts (57.1%) over a yellow/yellow-brown background (88.1%). Conclusion: Distribution of vessels, distribution of scales and the colour of scales, presence of brown/orange-brown dots and/or globules, yellow/yellow-orange crust and background colour (dull red vs. yellow/yellow-brown) of the plaques can be useful clues in the diagnosis of PPP and PPE.